Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
Portfolio Pulse from Vandana Singh
Roche Holdings AG announced that its Phase 3 ALINA study evaluating Alecensa, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival. Alecensa demonstrated a significant improvement in disease-free survival as adjuvant therapy in people with completely resected stage IB anaplastic lymphoma kinase-positive non-small cell lung cancer. The drug is now approved in over 100 countries as an initial treatment for ALK-positive, metastatic NSCLC, including in the United States, Europe, Japan, and China.
September 01, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche's Alecensa met its primary endpoint in the Phase 3 ALINA study, demonstrating a significant improvement in disease-free survival for lung cancer patients. This positive news could potentially boost investor confidence in Roche.
The positive results from the Phase 3 ALINA study indicate that Roche's Alecensa is effective in improving disease-free survival for lung cancer patients. This could potentially lead to increased sales of the drug, boosting Roche's revenues and potentially its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100